ClinicalTrials.gg
RecruitingNCT07046078Updated Jul 20, 2026

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

A Phase 2 interventional study of Allogeneic Hematopoietic Stem Cell Transplantation and Biospecimen Collection in Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia, sponsored by Fred Hutchinson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Fred Hutchinson Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing cytarabine in Leukemia, Biphenotypic, Acute — 4 open to participants now, 4 under way, none of them phase 3. Cytarabine · Leukemia, Biphenotypic, Acute.

Planned enrollment
10th of 14
20 · median 56
Started
2025
the only one that year
Phase 2
6 of 14
1 open now
Registered
14th of 14
by date
Lead sponsor
3 of 14
Fred Hutchinson Cancer Center

Among the 14 studies testing cytarabine in Leukemia, Biphenotypic, Acute, this one is the 10th largest by planned enrollment, is the only one that started in 2025, is one of 6 in phase 2, and was the 14th registered.

Leukemia, Biphenotypic, Acute

246 studies on the registry are indexed under Leukemia, Biphenotypic, Acute; 53 are open to participants now.

Browse Leukemia, Biphenotypic, Acute studies →

Open to participants now

4 of the 14 studies testing cytarabine in Leukemia, Biphenotypic, Acute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cytarabine

Cytarabine: first FDA approval 1969 (CYTARABINE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Leukemia, Biphenotypic, Acute studies recruiting now, 21 (45%) set no upper age limit and 21 (45%) stop at 75 or younger; 29 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing cytarabine in Leukemia, Biphenotypic, Acute, or all of them as a file.
02

Study summary

This phase II trial tests the safety, side effects, and how well combination chemotherapy with fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin (FLAG-Ida) followed immediately by reduced-intensity total body radiation therapy, called total body irradiation (TBI), and donor hematopoietic cell transplant (HCT) works in treating adults age 60 and older with newly diagnosed adverse-risk acute myeloid leukemia (AML) or other high-grade myeloid cancer. Despite advances in supportive care and the approval of more than 10 new drugs since 2017, the outcomes of older adults with adverse-risk acute myeloid leukemia and other high-grade myeloid cancers remains poor. Most patients are expected to die from their cancer or the consequences of treatment-related side effects. Donor HCT is a very important part of any curative-cancer treatment for these patients. However, while accepted as standard care for decades, this treatment exposes patients to long periods of drug-induced low blood cell counts and the problems associated with low blood counts, like infections and bleeding, which are associated with significant risk of chronic side effects and death. This study will use a different approach to the upfront curative-cancer treatment of older adults with an adverse-risk AML or other high-grade myeloid cancer. This study will use intense chemotherapy followed a few days later by lower-dose TBI and donor HCT. Chemotherapy drugs, such as idarubicin, fludarabine, high-dose cytarabine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. G-CSF helps the bone marrow make more white blood cells in patients with low white blood cell count due to cancer treatment. This approach allows effective treatment of cancer cells and overall reduction of the period of low blood cells counts. This decreases the risk for problems associated with low blood counts, such as infection and chronic side effects. Decreasing these are important for older adults who undergo HCT. This treatment strategy may improve treatment outcomes by allowing more patients to successfully undergo donor HCT and reduce the risk of low blood cell counts and the problems associated with low blood counts. Giving chemotherapy followed immediately by reduced-intensity TBI and donor HCT may be safe, tolerable and/or effective in treating adults age 60 and older with newly diagnosed adverse-risk AML or other high-grade myeloid cancer.

Read the detailed description

OUTLINE:

Patients receive granulocyte colony-stimulating factor subcutaneously (SC) once daily (QD) on days -9 to -4 or days -7 to -4 as clinically indicated, fludarabine intravenously (IV) over 30 minutes QD on days -8 to -4, cytarabine IV over 2 hours QD on days -8 to -4, and idarubicin IV over 60 minutes QD on days -8 to -6. Patients undergo TBI QD on days -1 and 0 or twice daily (BID) on day -1 or 0. Patients then undergo allogeneic HCT with unmodified peripheral blood stem cells IV on day 0 or 1 day after TBI as clinically indicated. Treatment continues in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo multigated acquisition scan (MUGA) or echocardiography (ECHO) during screening and as clinically indicated, undergo bone marrow biopsy and/or aspiration throughout the study and blood sample collection during follow up.

After completion of study treatment, patients are followed up at days 28, 56 and 80, at months 3 and 6 and at years 1 and 2.

03

Conditions studied

  • Acute Leukemia of Ambiguous Lineage
  • Acute Myeloid Leukemia
  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PARTICIPANTS: Age ≥ 60 years. Adults age \< 60 years are eligible if they are felt to be unsuitable candidates for myeloablative conditioning as per physician assessment
  • PARTICIPANTS: Ability to understand and willingness to sign a written document. Legally authorized representatives may sign and give informed consent on behalf of potential study participants
  • PARTICIPANTS: Newly diagnosed, untreated high-risk myeloid or mixed myeloid/lymphoid neoplasm:

    • Adverse-risk AML (using 2022 International Consensus Classification for disease categorization and 2022 European LeukemiaNet [ELN] criteria for molecular/cytogenetic risk assignment)
    • Acute leukemia of ambiguous lineage (using 2022 International Consensus Classification for disease categorization)
    • High-risk myelodysplastic neoplasm (MDS) (Molecular International Prognostic System [IPSS-M] moderate high, high, or very high, OR ≥ 10% blasts in blood or marrow)
    • High-risk chronic myelomonocytic leukemia (CMML) (clinical/molecular CMML-specific prognostic scoring system [CPSS-Mol] intermediate-2 or high, OR ≥ 10% blasts in blood or marrow)

      • Prior treatment of MDS or CMML with lower-intensity therapy (e.g., growth factors, erythropoiesis-stimulating agents, and lenalidomide) is permissible, but patients may not have received prior hypomethylating agents
  • PARTICIPANTS: Disease not requiring immediate anti-neoplastic therapy (e.g., presenting with leukopenia or pancytopenia), defined as a clinical scenario in which delay of systemic leukemia-directed treatment would be unsafe. Supportive cytoreduction with hydroxyurea for transient disease control is allowed, and does not constitute immediate anti-neoplastic treatment
  • PARTICIPANTS: Interest in pursuing HCT
  • PARTICIPANTS: Available caregiver
  • PARTICIPANTS: score ≥ 70; (ECOG) performance status 0-2
  • PARTICIPANTS: ≤ 2.5 x institutional unless elevation is thought to be due to hepatic infiltration by myeloid neoplasm, Gilbert's syndrome, or hemolysis
  • PARTICIPANTS: Serum creatinine ≤ 1.5 mg/dL
  • PARTICIPANTS: Prior autologous HCT is permissible if > 6 months after planned HCT on this study
  • PARTICIPANTS: Participants of must be willing to employ two highly effective and acceptable forms of 7 days before initiation of study treatment and for at least 12 months after HCT. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test during screening (within 2 weeks of treatment initiation, per Fred Hutch Cancer Center [FHCC] standard of care [SOC]), where WOCBP are defined as all female participants between 18-55 years of age, unless or with hysterectomy
  • PARTICIPANTS: -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • PARTICIPANTS: For patients with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of virus (HCV) infection must have been treated and cured. Patients with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load
  • PARTICIPANTS: Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen, as determined by the investigator, are eligible for this trial
  • DONORS: Patients must have an HLA-matched related donor, an HLA-matched or mismatched unrelated donor, or an HLA- haploidentical donor who meets standard Fred Hutchinson Cancer Center (FHCC) and/or National Marrow Donor Program (NMDP) or other donor center criteria for peripheral blood stem cell (PBSC) donation as follows:

    • HLA-matched related donor: related to the patient and genotypically or phenotypically identical for HLA-A, B, C, DRB1 and DQB1. Phenotypic identity must be confirmed by high-resolution typing
    • HLA-matched unrelated donor:

      • 10/10 matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing
      • Donors are excluded when preexisting immunoreactivity is identified that would jeopardize donor hematopoietic cell engraftment. The recommended procedure for patients with 10 of 10 HLA allele level (phenotypic) match is to obtain panel reactive antibody (PRA) screens to class I and class II antigens for all patients before HCT. If the PRA shows > 10% activity, then flow cytometric or B and T cell cytotoxic cross matches should be obtained. The donor should be excluded if any of the cytotoxic cross match assays are positive. A positive anti-donor cytotoxic crossmatch is an absolute donor exclusion
    • HLA-mismatched unrelated donor:

      • HLA-matching must be based on results of high resolution typing at HLA-A, -B, -C, -DRB1, and -DQ
      • Mismatched for a single allele without antigen mismatching at HLA-A, B, or C as defined by high resolution typing but otherwise matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing
      • HLA class I HLA-A, -B, -C allele matched donors allowing for any one or two DRB1 and/or DQB1 antigen/allele mismatch
      • Donor/recipient HLA mismatching at loci for which the patient is homozygous is not allowed (isolated rejection vector)
    • HLA-haploidentical donor:

      • Donors must be haploidentical relatives of the patients. Donor-recipient compatibility will be tested through HLA typing at high resolution for the HLA loci (-A, -B, -C, -DRB1, -DQB1). Donor and recipient should share at least 5/10 HLA loci

        • Donor age ≥ 12 years
        • Donor weight ≥ 40 kg
        • Ability of donors younger than 18 years of age to undergo apheresis without use of a vascular access device. Vein check must be performed and verified by an apheresis nurse prior to arrival
        • Donor must meet the selection criteria as defined by the Foundation of the Accreditation of Cell Therapy (FACT) and will be screened per the American Association of Blood Banks (AABB) guidelines
      • In case of more than one available haploidentical donor, preference should be given to younger age
      • Since detection of anti-donor-specific antibodies (anti-DSA) is associated with higher graft rejection rate, patients will be screened for anti-DSA pre-transplant. Use of donors requiring desensitization treatment of the patient are not permissible

Exclusion criteria

Exclusion Criteria:

  • PARTICIPANTS: Active central nervous system (CNS) disease
  • PARTICIPANTS: Decompensated congestive heart failure and/or uncontrolled arrhythmia and/or significant medical history of cardiac disease precluding HCT
  • PARTICIPANTS: Significant medical history of pulmonary disease and/or symptoms suggestive of pulmonary disease precluding allogeneic HCT
  • PARTICIPANTS: Treatment with any other approved or anti-leukemia agent(s) at the time of initiation of study treatment
  • PARTICIPANTS: Concomitant illness associated with a likely survival of \< 1 year
  • PARTICIPANTS: Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with antimicrobials and/or controlled or stable. Patients with fever thought to be secondary to myeloid are eligible
  • PARTICIPANTS: Known or to receiving any of the study drugs used in this trial, including post-transplant cyclophosphamide (PTCy)
  • PARTICIPANTS: Pregnancy or lactation
  • PARTICIPANTS: Psychiatric illness/social situations that would limit compliance with study requirements
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment (FLAG-Ida, TBI, HCT)

    Patients receive granulocyte colony-stimulating factor SC QD on days -9 to -4 or days -7 to -4 as clinically indicated, fludarabine IV over 30 minutes QD on days -8 to -4, cytarabine IV over 2 hours QD on days -8 to -4, and idarubicin IV over 60 minutes QD on days -8 to -6. Patients undergo TBI QD on days -1 and 0 or BID on day -1 or 0. Patients then undergo allogeneic HCT with unmodified peripheral blood stem cells IV on day 0 or 1 day after TBI as clinically indicated. Treatment continues in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo MUGA or ECHO during screening and as clinically indicated, undergo bone marrow biopsy and/or aspiration throughout the study and blood sample collection during follow up.

    Procedure: Allogeneic Hematopoietic Stem Cell Transplantation · Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Drug: Cytarabine · Procedure: Echocardiography Test · Drug: Fludarabine · Drug: Idarubicin · Procedure: Multigated Acquisition Scan · Biological: Peripheral Blood Stem Cell · Other: Questionnaire Administration · Biological: Recombinant Granulocyte Colony-Stimulating Factor · Radiation: Total-Body Irradiation

Interventions

  • ProcedureAllogeneic Hematopoietic Stem Cell Transplantation

    Undergo allogeneic HCT

    Also known as: Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow biopsy and/or aspiration

  • ProcedureBone Marrow Biopsy

    Undergo bone marrow biopsy and/or aspiration

    Also known as: Biopsy of Bone Marrow, Biopsy, Bone Marrow

  • Given IV

    Also known as: .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453

  • ProcedureEchocardiography Test

    Undergo ECHO

    Also known as: EC, Echocardiography

  • Given IV

    Also known as: Fluradosa

  • Given IV

    Also known as: 4-Demethoxydaunomycin, 4-Demethoxydaunorubicin, 4-DMDR

  • ProcedureMultigated Acquisition Scan

    Undergo MUGA

    Also known as: Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning

  • Given IV

    Also known as: PBSC, Peripheral Blood Stem Cells, peripheral stem cell, Peripheral Stem Cells

  • OtherQuestionnaire Administration

    Ancillary studies

  • Given SC

    Also known as: Recombinant Colony-Stimulating Factor 3, rhG-CSF

  • RadiationTotal-Body Irradiation

    Undergo TBI

    Also known as: SCT_TBI, TBI, Total Body Irradiation, Whole Body, Whole Body Irradiation, Whole-Body Irradiation

06

What researchers measure

Primary outcomes

  1. Proportion of participants starting study treatment with FLAG-Ida within 42 days of the date of informed consent

    Will evaluate the proportion of participants starting study treatment with FLAG-Ida within 42 days of the date of informed consent.

    Time frame: Up to 42 days after informed consent

Secondary outcomes

  1. Number of patients transplanted

    Will evaluate the number of patients transplanted.

    Time frame: Up to 2 years

  2. Time from day of consent to day of allogeneic hematopoietic cell transplant (HCT)

    Will evaluate time from day of consent to day of allogeneic HCT.

    Time frame: From day of consent to day of allogeneic hematopoietic cell transplant (HCT)

  3. Reasons for failure to undergo allogeneic transplantation (allo-HCT)

    Identified reasons for failure to undergo allogeneic transplantation (e.g., lack of suitable donor, complications of disease) will be systematically categorized and quantitatively reported.

    Time frame: Up to 2 years following Screening enrollment

  4. Incidence of adverse events

    Will evaluate the number of participants with non-hematologic adverse events ≥ grade 3. Will use the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 for toxicity and adverse event reporting.

    Time frame: From start of conditioning (Day -9) to study-defined neutrophil engraftment, or adversely, to graft failure

  5. Neutrophil count recovery

    Will evaluate the time to neutrophil count recovery. The day of neutrophil recovery will be the 1st day of 2 consecutive days of absolute neutrophil count at or above 500/µL.

    Time frame: Day 0 to study-defined neutrophil engraftment, or adversely, to graft failure.

  6. Platelet count recovery

    Will evaluate the time to platelet count recovery. Platelet engraftment will be defined as the first of 7 days of a platelet count \> 20,000/µl without subsequent transfusions for 7 days.

    Time frame: Day 0 to study-defined platelet engraftment

  7. Incidence of severe adverse events

    Will evaluate the number of participants with any severe adverse event. Will use the NCI CTCAE version 5.0 for toxicity and adverse event reporting.

    Time frame: From start of conditioning (Day -9) to study-defined neutrophil engraftment, or adversely, to graft failure

  8. Non-relapse mortality (NRM)

    Will evaluate the number of participants experiencing NRM by day +100 after HCT.

    Time frame: Up to day 100 after HCT

  9. Rate of CD3 chimerism

    Will evaluate the rate of peripheral blood CD3 chimerism at day 80 (±7 days). Mixed or full donor chimerism will be evidence of donor engraftment. Full chimerism: \> 95% donor CD3+ T cells. Mixed chimerism: the detection of peripheral blood donor T cells (CD3+) and granulocytes (CD33+) as a proportion of the total peripheral blood T cell and granulocyte population, respectively.

    Time frame: At day 80 (+/- 7 days)

  10. Rate of CD33 chimerism

    Will evaluate the rate of peripheral blood CD33 chimerism at day 80 (±7 days). Mixed or full donor chimerism will be evidence of donor engraftment. Full chimerism: \> 95% donor CD3+ T cells. Mixed chimerism: the detection of peripheral blood donor T cells (CD3+) and granulocytes (CD33+) as a proportion of the total peripheral blood T cell and granulocyte population, respectively.

    Time frame: At day 80 (+/- 7 days)

  11. Incidence of acute graft versus host disease (GVHD)

    Will evaluate the cumulative incidence of grade 2-4 acute GVHD by day +100.

    Time frame: Up to day 100

  12. Incidence of chronic GVHD

    Will evaluate the cumulative incidence of chronic GVHD requiring systemic immunosuppressive therapy by day +365.

    Time frame: Up to day 365

  13. Number of participants achieving complete remission or complete remission with incomplete hematologic recovery by day +42

    Will evaluate the number of participants achieving complete remission or complete remission with incomplete hematologic recovery by day +42. Will be determined by peripheral blood count and bone marrow evaluation and categorized according to the 2022 European LeukemiaNet criteria.

    Time frame: Up to day 42

  14. Measurable ("minimal") residual disease (MRD)-negativity

    Will evaluate the number of participants achieving MRD-negativity by day +42. Will be determined by peripheral blood count and bone marrow evaluation and categorized according to the 2022 European LeukemiaNet criteria.

    Time frame: Up to day 42

  15. Relapse-free survival

    Will evaluate relapse-free survival at day +180. Will be determined by peripheral blood count and bone marrow evaluation and categorized according to the 2022 European LeukemiaNet criteria.

    Time frame: At day 180

  16. Overall survival

    Will evaluate overall survival at day +180.

    Time frame: At day 180

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jun 2027, 21 months after the start.

Of 42 phase 2 interventional studies under Leukemia, Biphenotypic, Acute, half reached primary completion within 102 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 153. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2025
First posted
Jul 1, 2025
StartActual
Sep 26, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2029
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07046078
Responsible party
Sponsor
First posted
Jul 1, 2025
Start date
Sep 26, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Jul 20, 2026

Study contacts

Filippo Milano, MD, PhD
Contact
fmilano@fredhutch.org
206-667-5925
Filippo Milano, MD, PhD
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cytarabine · Fludarabine · Idarubicin · Peripheral Blood Stem Cell · Recombinant Granulocyte Colony-Stimulating Factor

Start the discussion